Join the Skyrizi group to help and get support from people like you.
Skyrizi News
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 – For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission...
FDA Approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for adults with moderately ...
Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely...
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ – AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,...
Further information
Related condition support groups
Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis, Psoriasis